Dave Maloney is an accomplished scientist and biotechnology executive who has 15 years of drug discovery experience in across the public and private sectors. Prior to founding Veralox, Dave was a Group Leader in Chemistry and co-led an interdisciplinary project team at NIH’s National Center for Advancing Translational Sciences (NCATS). During this time, he managed a project portfolio encompassing a broad range of therapeutic areas and target classes which involved close collaboration and interaction with leading researchers from around the world. Several of his programs were out-licensed to biotech and advanced towards the clinic (including VLX-1005).  He is well-versed in implementing and managing R&D efforts with domestic and international CROs to efficiency advance development programs. He is co-author on over 100 scientific publications and co-inventor on more than 15 composition of matter patents. Dave earned a Bachelor of Science in Chemistry from the University of Vermont, a PhD in organic chemistry from the University of Virginia and completed his postdoctoral training at Memorial Sloan-Kettering Cancer Center.

• 

  Chief Scientific Officer (CSO) in Veralox Therapeutics

  Developing new therapies for life-threatening immuno-inflammatory diseases

• 

  Co-Founder in Veralox Therapeutics

  Developing new therapies for life-threatening immuno-inflammatory diseases